Myelodysplastic syndrome
Conditions
Interventions
Experimental Group:Supportive treatments such as blood transfusion, anti-infection, EPO, G-CSF, TPO, etc., combined with immunomodulators, immunosuppressants, demethylating drugs, etc. for 12 weeks of
Control Group:Supportive treatments such as blood transfusion anti-infection EPO G-CSF and TPO as well as treatments such as immunomodulators immunosuppressants and demethylating drugs for 12 weeks.
Sponsors
Hubei Provincial Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Age = 18 years old; (2) Meets the diagnostic criteria of MDS in Western medicine; (3) IPSS-R score = 3.5 points risk stratification is classified as low risk; (4) Complies with the traditional Chinese medicine diagnosis criteria of "spleen kidney deficiency and toxin stasis blockage type" (referring to the "Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Myelodysplastic Syndrome (2018 Edition)" and the "Guidelines for Traditional Chinese Medicine Clinical Practice of Myelodysplastic Syndrome"); (5) Agree to undergo follow-up; (6) Those who voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Secondary MDS (2) Patients with other hematological or non-hematological tumors; (3) Those with relatively severe organic lesions such as cardiovascular and cerebrovascular diseases liver and kidney diseases as well as peripheral neuropathy; (4) Pregnant or lactating women; (5) Patients with mental disorders who cannot cooperate with treatment patients with Class A and B infectious diseases patients with active hepatitis and patients currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall treatment response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM Syndrome scoring;The number of red blood cell/platelet transfusions and the independence of red blood cell/platelet transfusions;Survival analysis;Infection rate and infection-related mortality rate;Bleeding score;Analysis of evidence elements; | — |
Countries
China
Contacts
Public ContactChenbin
Hubei Provincial Traditional Chinese Medicine Hospital
Outcome results
None listed